# Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19

> **NCT04736901** · — · COMPLETED · sponsor: **Ain Shams University** · enrollment: 90 (actual)

## Conditions studied

- Covid19
- Corona Virus Infection
- Hypercoagulability

## Interventions

- **DRUG:** Enoxaparin
- **DRUG:** Enoxaparin
- **DRUG:** Rivaroxaban
- **DRUG:** Rivaroxaban
- **DRUG:** Apixaban
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT04736901
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2021-10-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2022-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04736901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04736901, "Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04736901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*